Loading...
Market
What will be the market share of zanidatamab-hrii in HER2+ BTC treatments by the end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Market analysis reports from pharmaceutical industry analysts
Story
FDA Approves Jazz's Zanidatamab for HER2+ Biliary Cancer with 52% Response Rate
Nov 21, 2024, 12:36 AM
The U.S. Food and Drug Administration (FDA) has approved a new drug, zanidatamab-hrii (Ziihera), developed by Jazz Pharmaceuticals, for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC). This approval marks a significant advancement in the treatment of this specific cancer type, with the drug showing a 52% response rate and a median duration of response of 14.9 months.
View original story
Similar markets
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
Over 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%